Roquette Invests €25 million for Polyols at its Site in Lestrem, France

Article

Roquette is investing €25 million at its site in Lestrem, France to strengthen its position in the polyols market.

Roquette, a company focused on providing plant-based ingredients, plant proteins, and pharmaceutical excipients, announced on March 22, 2022 an investment plan for €25 million (approximately USD $27.5 million) for liquid and powder polyols between 2022 and 2024 at its site in Lestrem, France. The investment will establish a strong, reliable supply for the future and strengthen the company’s position as a leader in the polyols market.

Polyols are key pharmaceutical excipients in oral dosage forms. They are directly compressible and aid in the formulation of swallowable, chewable, or dispersible tablets. The higher purity grades of polyols are also APIs and are widely used in injectable solutions. They are also used in oral care applications because of their functionalities as non-crystallizing humectant, non-cariogenic, or shelf-life enhancer.

The investment will improve equipment efficiency, increase safety standards, standardize industrial operations, and improve overall production performance. The investment will also ensure a sustainable supply of polyols in the market and meet customers’ increasing expectations for greater flexibility.

Source: Roquette

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Related Content
© 2025 MJH Life Sciences

All rights reserved.